Tumor biology, treatment patterns, and recurrence in breast cancer patients aged 70–79 vs ≥ 80 years: a large-scale registry analysis

Clinical and biological differences between women aged 70-79 and those ≥ 80 underscore the need for age-adapted, individualized BC management. Treatment decisions should carefully balance expected benefit against comorbidity burden and functional status. Refining age-specific treatment strategies may help to improve outcomes and quality of life, although this analysis cannot determine the effects of specific strategies in this growing patient population.